These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 17724278)

  • 1. Stability of target hemoglobin levels during the first year of epoetin treatment in patients with chronic kidney disease.
    De Nicola L; Conte G; Chiodini P; Cianciaruso B; Pota A; Bellizzi V; Tirino G; Avino D; Catapano F; Minutolo R
    Clin J Am Soc Nephrol; 2007 Sep; 2(5):938-46. PubMed ID: 17724278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
    Sulowicz W; Locatelli F; Ryckelynck JP; Balla J; Csiky B; Harris K; Ehrhard P; Beyer U;
    Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anemia management and association of race with mortality and hospitalization in a large not-for-profit dialysis organization.
    Servilla KS; Singh AK; Hunt WC; Harford AM; Miskulin D; Meyer KB; Bedrick EJ; Rohrscheib MR; Tzamaloukas AH; Johnson HK; Zager PG
    Am J Kidney Dis; 2009 Sep; 54(3):498-510. PubMed ID: 19628315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial.
    Klinger M; Arias M; Vargemezis V; Besarab A; Sulowicz W; Gerntholtz T; Ciechanowski K; Dougherty FC; Beyer U
    Am J Kidney Dis; 2007 Dec; 50(6):989-1000. PubMed ID: 18037099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients.
    Regidor DL; Kopple JD; Kovesdy CP; Kilpatrick RD; McAllister CJ; Aronovitz J; Greenland S; Kalantar-Zadeh K
    J Am Soc Nephrol; 2006 Apr; 17(4):1181-91. PubMed ID: 16565261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epoetin delta, erythropoietin produced in a human cell line, in the management of anaemia in predialysis chronic kidney disease patients.
    Kwan JT; Pratt RD;
    Curr Med Res Opin; 2007 Feb; 23(2):307-11. PubMed ID: 17288685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Normalization of hemoglobin level in patients with chronic kidney disease and anemia.
    Drüeke TB; Locatelli F; Clyne N; Eckardt KU; Macdougall IC; Tsakiris D; Burger HU; Scherhag A;
    N Engl J Med; 2006 Nov; 355(20):2071-84. PubMed ID: 17108342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exceeding hemoglobin target levels in US hemodialysis patients receiving epoetin, 1999 to 2002.
    Foley RN; Zhang R; Gilbertson DT; Dunning S; Ishani A; Collins AJ
    Hemodial Int; 2007 Jul; 11(3):333-9. PubMed ID: 17576299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
    Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
    Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epoetin alfa once every 2 weeks is effective for initiation of treatment of anemia of chronic kidney disease.
    Benz R; Schmidt R; Kelly K; Wolfson M
    Clin J Am Soc Nephrol; 2007 Mar; 2(2):215-21. PubMed ID: 17699416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perihospitalization hemoglobin-epoetin associations in U.S. hemodialysis patients, 1998 to 2003.
    Solid CA; Foley RN; Gilbertson DT; Collins AJ
    Hemodial Int; 2007 Oct; 11(4):442-7. PubMed ID: 17922742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of once-weekly intravenous epoetin alfa in maintaining hemoglobin levels in hemodialysis patients.
    Locatelli F; Villa G; Messa P; Filippini A; Cannella G; De Ferrari G; Naso A; Rossi E; Formica M; Lombardi L; Rotolo U; Conte F
    J Nephrol; 2008; 21(3):412-20. PubMed ID: 18587731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of early correction of anemia on the progression of CKD.
    Rossert J; Levin A; Roger SD; Hörl WH; Fouqueray B; Gassmann-Mayer C; Frei D; McClellan WM
    Am J Kidney Dis; 2006 May; 47(5):738-50. PubMed ID: 16632012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hemoglobin targets and blood transfusions in hemodialysis patients without symptomatic cardiac disease receiving erythropoietin therapy.
    Foley RN; Curtis BM; Parfrey PS
    Clin J Am Soc Nephrol; 2008 Nov; 3(6):1669-75. PubMed ID: 18922988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Regarding the optimal hemoglobin target range in renal anemia].
    Maurin N
    Med Klin (Munich); 2008 Sep; 103(9):633-7. PubMed ID: 18813886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Do we know the correct hemoglobin target for anemic patients with chronic kidney disease?
    Foley RN
    Clin J Am Soc Nephrol; 2006 Jul; 1(4):678-84. PubMed ID: 17699272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Is the management of anemia in hemodialysis patients improving in France? Results of the DiaNE study].
    Kessler M; Landais P; Canivet E; Yver L; Bataille P; Brillet G; Commenges B; Koné S
    Nephrol Ther; 2009 Apr; 5(2):114-21. PubMed ID: 19042175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Haemoglobin at time of referral prior to dialysis predicts survival: an association of haemoglobin with long-term outcomes.
    Levin A; Djurdjev O; Duncan J; Rosenbaum D; Werb R
    Nephrol Dial Transplant; 2006 Feb; 21(2):370-7. PubMed ID: 16249203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of epoetin zeta for correction of renal anemia in hemodialysis patients with thalassemia minor.
    Kumchev E; Koytchev R; Dimitrakov D; Stavrev P; Tsochev G; Siebert-Weigel M
    Adv Ther; 2008 Dec; 25(12):1375-8. PubMed ID: 19043680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Greater Epoetin alfa (EPO) doses and short-term mortality risk among hemodialysis patients with hemoglobin levels less than 11 g/dL.
    Bradbury BD; Do TP; Winkelmayer WC; Critchlow CW; Brookhart MA
    Pharmacoepidemiol Drug Saf; 2009 Oct; 18(10):932-40. PubMed ID: 19572312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.